Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Garonit Pharmaceutical, Inc.
EIR
•Garonit Pharmaceutical, Inc.•July 6, 2023

Garonit Pharmaceutical, Inc. – FDA EIR, Jul 6, 2023

Record Details

An FDA surveillance inspection of Garonit Pharmaceutical Inc., an Active Pharmaceutical Ingredients (API) manufacturer of Chlorhexidine Gluconate 20% USP, was conducted from June 27 to July 06, 2023. The inspection adhered to Compliance Programs for Animal Drug Manufacturing and API Process Inspections, as well as ICH Q7 Good Manufacturing Guidance for Active Pharmaceutical Ingredients.

The inspection revealed two main violations, leading to a Form FDA 483. The first, a repeat observation, cited the company's failure to extend investigations to all potentially affected batches. This specifically related to a PCMX contamination incident in a Chlorhexidine Gluconate 20% USP lot, where the investigation, despite tracing the root cause to a raw material supplier's cleaning agent, was not expanded to other API lots manufactured using the same raw material. Additionally, the complaint handling procedure lacked defined timelines for initiating and closing investigations.

The second observation concerned the failure to adequately document and investigate deviations. This included not initiating a deviation or investigation when a batch of Chlorhexidine Gluconate 20% USP was voided due to unexplained overnight weight variability, potentially from a water leak. Furthermore, a deviation report for a prolonged low humidity excursion in a stability chamber, where API lots were stored, remained open without conclusion or documented justification for keeping samples in the affected chamber, contrary to company procedures.

Garonit Pharmaceutical Inc.'s management acknowledged the findings and committed to submitting a written response to the FDA within 15 business days, detailing corrective actions. A verbal discussion also emphasized the need to enhance water sampling procedures to ensure critical sample handling details are comprehensively documented.

Company
Garonit Pharmaceutical, Inc.
Inspection date
July 6, 2023
Product type
veterinary
Office
Food and Drug Administration
People
  • Rohit Garg (company_representative)
  • David Mazzarell (other)
  • Frank Berstler (recipient)
  • Yesha Kathrani (company_representative)
  • Janet A. Rajan (Investigator)
View Company Profile

ID · 40f560e8-cb0e-46bb-bff2-9557ac414f4f

Violation Codes1
21 CFR 820.198

Full citation text and observation details available on the Dashboard.

Other documents for Garonit Pharmaceutical, Inc.
  • 483 - 2023-07-06July 6, 2023
  • 483 - 2020-10-20October 20, 2020

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Garonit Pharmaceutical, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.